阿斯利康发布2026年业绩指引，预计核心每股收益两位数增长

Core Viewpoint - AstraZeneca expects a double-digit percentage growth in core earnings per share by 2026, with total revenue projected to grow in the mid-to-high single digits at constant exchange rates [1] Group 1: Clinical Trials and Product Development - The company plans to announce results from up to 20 advanced clinical trials by 2026, focusing on oncology, respiratory diseases, and rare diseases [1] - Key trials include AVANZAR and TROPION-Lung07 [1] - The oral GLP-1 drug elecoglipron has entered late-stage clinical trials, and the company has partnered with CSPC Pharmaceutical Group to accelerate its entry into the weight loss drug market [1] Group 2: Financial Outlook and Shareholder Returns - AstraZeneca has increased its annual dividend by approximately 3% to $3.30 [1] - The company reaffirms its long-term goal of achieving $80 billion in revenue by 2030 [1]